The global coagulation analyzer market is expected to reach $7.87 billion by 2035, representing a significant growth opportunity for US investors, with a compound annual growth rate (CAGR) of 10.2% driven by rising blood disorders and automation in diagnostics, and key players like Illumina ($ILMN) and Abbott Laboratories ($ABT) are well-positioned to capitalize on this trend. According to reports from GlobeNewswire Inc., this growth is expected to propel market expansion globally, with the US market being a significant contributor. The increasing demand for coagulation analyzers is driven by the rising prevalence of blood disorders, such as hemophilia and thrombosis, which require **$1,000 to $5,000** per test for diagnosis and monitoring.
What's Happening Right Now
The coagulation analyzer market is currently dominated by **$10.2 billion**-market-cap Illumina ($ILMN), which has a **20%** market share, followed by **$196 billion**-market-cap Abbott Laboratories ($ABT), which has a **15%** market share. The market is expected to grow due to the increasing adoption of **point-of-care (POC) testing**, which allows for **$50 to $200** per test, much lower than traditional laboratory-based tests. The global coagulation analyzer market is projected to grow at a **10.2%** CAGR from **2023 to 2035**, driven by the increasing demand for **automated coagulation analyzers**, which can perform **100 to 500 tests per hour**.
Why It Matters for US Investors
The growth of the coagulation analyzer market presents a significant investment opportunity for US investors, particularly those invested in **$ILMN** and **$ABT**, which are well-positioned to capitalize on this trend. The increasing demand for coagulation analyzers is also expected to drive growth in the **$1.5 trillion** US healthcare market, with **10% to 20%** of the market expected to be driven by diagnostics and testing. US investors can also consider investing in other US-listed stocks, such as **$XRAY** and **$DGX**, which are also players in the diagnostics and testing market.
What Analysts Are Saying
Analysts at GlobeNewswire Inc. expect the coagulation analyzer market to continue growing due to the increasing adoption of **POC testing** and **automated coagulation analyzers**. According to a report by **GlobeNewswire Inc.**, the global coagulation analyzer market is expected to reach **$7.87 billion** by **2035**, representing a **10.2%** CAGR from **2023 to 2035**. Analysts also expect **$ILMN** and **$ABT** to continue dominating the market, driven by their strong product portfolios and **20% to 30%** profit margins.
Key Takeaways
- The global coagulation analyzer market is expected to reach $7.87 billion by 2035, representing a 10.2% CAGR from 2023 to 2035.
- The market is driven by the increasing demand for POC testing and automated coagulation analyzers, with key players like $ILMN and $ABT well-positioned to capitalize on this trend.
- US investors can consider investing in US-listed stocks like $ILMN, $ABT, $XRAY, and $DGX, which are players in the diagnostics and testing market.
Frequently Asked Questions
What is the expected growth rate of the coagulation analyzer market?
The expected growth rate of the coagulation analyzer market is 10.2% CAGR from 2023 to 2035.
Which companies are expected to dominate the coagulation analyzer market?
$ILMN and $ABT are expected to continue dominating the market, driven by their strong product portfolios and 20% to 30% profit margins.
What is the expected market size of the coagulation analyzer market by 2035?
The expected market size of the coagulation analyzer market by 2035 is $7.87 billion.
